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Abstract Antibiotic resistance in urinary tract infections
(UTIs) can cause significant complications without quick de-
tection and appropriate treatment. We describe a new approach
to capture, concentrate and prepare amplification-ready DNA
from antibiotic resistant bacteria in human urine samples.
Klebsiella pneumoniae NCTC13443 (blaCTX-M-15 positive)
spiked into filtered human urine was used as a model system.
Bacteria were captured using anion exchange diaethy-
laminoethyl (DEAE) magnetic microparticles and concentrated
200-fold within ~3.5 min using a custom, valve-less
microfluidic chip. Eight samples were processed in parallel,
and DNA was released using heat lysis from an integrated
resistive heater. The crude cell lysate was used for real time
Recombinase Polymerase Amplification (RPA) of the blaCTX-
M-15 gene. The end to end processing time was approximately
15 min with a limit of detection of 1000 bacteria in 1 mL urine.
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1 Introduction
Antibiotic resistance is a worldwide public health concern. As
pathogens evolve new antibiotic resistance mechanisms, even
simple infections will become difficult to treat (O’Neill 2014).
Rapid detection of antibiotic resistant pathogens is key
for targeted and effective patient treatment and to limit
the development of further resistance caused by the use
of ineffective or broad-spectrum antibiotics. Current rou-
tine clinical tests to detect antibiotic resistant bacteria
rely on time-consuming cell culture, or on molecular
detection by polymerase chain reaction (PCR) based ap-
proaches that require dedicated laboratories and expert
users. Therefore, rapid and sensitive Point-of-Care (PoC)
tests are critical to enable directed diagnosis of antibi-
otic resistant pathogens as the basis for prescribing
practice.
Urinary tract infections (UTIs) are common bacterial infec-
tions that account for substantial health costs and morbidity
(Abbo and Hooton 2014). Klebsiella pneumoniae and other
extended spectrum β-lactamase (ESBL) and carbapenemase
producing Enterobacteriaceae have emerged as a major
healthcare issue in the last 10–20 years (Pitout et al. 2015).
Resistance to extended spectrum β-lactam and carbapenem
antibiotics have been classed as a serious hazard in the USA
where 26,000 cases were reported in 2013, causing 1700
deaths (Control and Prevention 2013). The CTX-M enzyme
family is the most prevalent amongst the wide range of ESBL
enzymes, conferring resistance to key β-lactam antibiotics
(Bonnet 2004; D’Andrea et al. 2013; Zhao and Hu 2013) in
at least 26 bacterial species, residing in both nosocomial and
community environments (Zhao and Hu 2013). Therefore, a
gene encoding for the widespread CTX-M-15 isoform,
blaCTX-M-15, which encodes a protein with enhanced catalytic
activity (Zhao and Hu 2013), is an ideal candidate for
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demonstrating rapid PoC detection system for antibiotic resis-
tant pathogens.
Significant advances in both highly sensitive and rapid
(<20 min) isothermal DNA amplification techniques
(reviewed by Niemz et al. 2011), as well as their implementa-
tion on easy automatable and miniaturized microfluidic plat-
forms, have resulted in promising developments in PoC bac-
terial detection systems. For example, rolling circle amplifica-
tion (RCA) has been integrated with microfluidic chips to
detect Salmonella (Sato et al. 2010) and Pseudomonas
(Kuhnemund et al. 2014). Loop-mediated isothermal amplifi-
cation (LAMP) has been performed on various microfluidic
platforms, including polymer chips (Tourlousse et al. 2012),
PDMS chips (Fang et al. 2010; Wang et al. 2011) and centrif-
ugal lab-on-a-disc platform (Kim et al. 2014) to detect a vari-
ety of human, water and food borne bacteria and viruses.
Recombinase polymerase amplification (RPA) has also been
implemented on micro-devices. This is an isothermal DNA
amplification technique with distinct advantages including a
lower incubation temperature, ease of primer design, high
specificity and sensitivity for the target gene. RPA uses two
oligonucleotide primers to prime the enzymatic amplification
of a DNA fragment of interest, while its quantity can be mon-
itored using fluorescent probes. The utility of this technology
has now been demonstrated for the detection of a variety of
pathogens (Euler et al. 2013; Ahmed et al. 2014; Kersting
et al. 2014a, b; Xia et al. 2015), including real-time RPA on
microfluidic devices (Lutz et al. 2009; Kalsi et al. 2015;
Tortajada-Genaro et al. 2015; Tsaloglou et al. 2015). Most
importantly, RPA has a high tolerance to crude samples, for
example undiluted human urine (Krolov et al. 2014), without
the need for extensive purification steps.
Despite significant progress in microfluidic based DNA
detection assays, the development of a complete Bsample
in-answer out^ device for PoC tests still faces some important
obstacles. A key pre-requisite in any microfluidic PoC molec-
ular diagnostic system is sample pre-processing to interface
real clinical samples of several mL to the μL to nL volumes
used in microfluidic molecular assays (Cui et al. 2015). An
ideal sample preparation system should include a simple cell
capture and pre-concentration unit as well as a DNA prepara-
tion method. Sample pre-concentration for pathogen analysis
is arguably the most challenging part of a DNA-based assay.
One of the simplest methods for capturing bacteria in solution
is the use of small magnetic beads with various coatings. This
approach can be easily incorporated into a passive sample
preparation device, and requires no complex fluidics.
Antibody coated beads attach to surface antigens of specific
bacteria and can be used to separate them from a mixed com-
munity for detection by fluorescence microscopy (Wen et al.
2013), PCR (Beyor et al. 2009), loop mediated isothermal
amplification (Wang et al. 2011) or transcriptome studies
(Dai et al. 2011). Aptamers can also be used instead of
antibodies as the capture molecule (Suh et al. 2014).
However, some of these approaches have significant limita-
tions such as requiring the bacteria to be in a particular buffer
to facilitate capture, or requiring a nucleic acid extraction after
cell capture (Dai et al. 2011; Suh et al. 2014), in addition to the
time and financial burden of producing the capture molecules.
Furthermore, antibody approaches are limited to only a single
known target organism, which has already been isolated and
cultured, and is assumed to represent the wild-type strains.
Such detection approaches that target specific organisms in-
stead of the genes responsible for antibiotic resistance, might
miss species with emerging resistance (i.e. those that contain a
newly acquired resistance gene). All these issues make anti-
body and aptamer coated capture beads unsuitable for bacte-
rial community-level multiplex analysis.
An alternative, yet little-explored approach to capture and
concentrate microbes from liquid samples is ion-exchange
magnetic beads. Yang et al. (2011) showed how anion-
exchange diethylaminoethyl (DEAE) coated magnetic beads
could improve the detection limit of a PCR-based assay for
Escherichia coli (Gram-negative) and Agrobacterium
tumefaciens (Gram-positive) by 2–3 orders of magnitude
compared to that without pre-concentration of the organisms.
In different work, it was found that DEAE anion-exchange
were superior to another four types of ion exchange beads,
including beads coated with polyaspartic acid (PAA), giving
the highest capture efficiency for E. coli, Enterococcus spp.
and Salmonella spp. (Guo et al. 2009). However, the compat-
ibility of this method with DNA amplification protocols was
not investigated. Importantly, in both studies the protocols
were developed to isolate bacteria suspended in water, which
is certainly not representative of clinical samples. While sur-
face functionalized magnetic beads show great promise for
bacterial capture and pre-concentration, none of this work
has been performed with clinical samples, nor has the poten-
tial for direct interfacing (i.e. without purification or washing)
with DNA amplification been explored.
Bacteria in solution are usually concentrated using lab scale
centrifugation, which has also been implemented on a micro-
scale using microstructures fabricated on a compact disc (CD)
(Cho et al. 2014; Kong et al. 2015). More complex cell con-
centration methods involve manipulating the flow of cells
using size or charge based differentiation methods (Pratt
et al. 2011). Simpler cell capture approaches using a physical
substrate, such as a filter, (Baier et al. 2009; Gulliksen et al.
2012; Gan et al. 2014; Zhuang et al. 2015a, b) or beads (Cho
et al. 2007; Ritzi-Lehnert et al. 2011) have also been demon-
strated on microfluidic platforms. However, these methods
require electrical power to control the sample flow or the mag-
netic beads. Other approaches for sample preparation involve
cell lysis followed by DNA concentration using solid phase
extraction on microdevices (Kulinski et al. 2009; Mahalanabis
et al. 2009, 2010; Van Heirstraeten et al. 2014; Sun et al.
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2015). In microfluidic systems, cell lysis is often achieved
chemically using varying combinations of surfactants, en-
zymes and chaotropic agents (Jebrail et al. 2014), however,
this necessitates a variety of chambers, reagents and control
structures to be built into the device. Thermal methods, where
cells are lysed at high temperature to release DNA, are popular
due to their simplicity of implementation (Marshall et al.
2012).
In this study, we describe a simple streamlined method to
rapidly capture, pre-concentrate and lyse bacterial pathogens
from human urine for subsequent detection of antibiotic resis-
tance genes. We simulate clinical samples by adding bacteria
to filtered human urine, demonstrating a proof-of-concept
sample processing protocol. This includes capture of bacteria
from human urine using anion-exchangemagnetic beads, con-
centration of the sample from 1 mL into small (~6 μL) vol-
umes using a using an 8 channel, valve-less magnetic
microfluidic device in just 3.5 min, and an optional heat lysis
on the device to provide amplification-ready DNA. The sim-
ple sample processing method is coupled with a highly robust
DNA amplification technique, Recombinase Polymerase
Amplification (RPA). The protocol does not include any
washing steps or buffer replacement for DNA purification.
Combining this sample preparation approach with RPA of
the blaCTX-M-15 gene, has led to a rapid assay for antibiotic
resistance detection, with a sample preparation time of 10 min
and RPA run time of 20 min for a highly sensitive of detection
1000 bacteria colony forming units. We demonstrate the util-
ity of this method in human urine samples spiked with antibi-
otic resistantKlebsiella pneumoniae, thus proving its potential
clinical relevance.
2 Materials and methods
2.1 Bacterial culture
The target organism used to develop this test was Klebsiella
pneumoniae NCTC 13443, isolated from a human clinical
sample and obtained from the National Collection of Type
Cultures at Public Health England (PHE). The genome of this
strain has been sequenced (EBI accession number
SAMEA2742597) and is known to contain genes for the
ESBL CTX-M-15 and the carbapenemase NDM-1. Bacteria
were maintained on Tryptone Soy Agar (TSA) plates. To en-
sure healthy growth, bacteria were transferred onto new plates
biweekly and following an overnight incubation at 37 °C, they
were stored at 4 °C. To produce liquid cultures for experi-
ments, a bacterial colony was transferred from a plate into
15 mL of Tryptone Soy Broth (TSB) medium and the culture
was incubated at 37 °C overnight. The following morning the
culture was diluted 20-fold with new TSB medium and incu-
bated at 37 °C for a further 3 h to ensure that cells were in early
exponential growth phase. These cultures were used for ex-
periments by diluting to the desired concentration into donat-
ed human urine (at least 100-fold dilution with 0.2 μm filter-
sterilized urine).
2.2 Cell counts
The concentration of bacteria in the parent culture was count-
ed using the Miles and Misra dilution and plating technique as
described previously (Wand et al. 2015). This was done pre
and post capture when evaluating capture efficiency of the
anion-exchange beads, or only pre-capture when conducting
titrations for DNA amplification. Several dilutions of the cul-
ture were prepared in Phosphate Buffered Saline (PBS) and,
for every dilution, three 20 μL aliquots were dispensed onto
duplicate TSA plates. Colonies were counted after an over-
night incubation at 37 °C and these counts were used to infer
the number of viable bacteria in the original culture, expressed
in colony forming units (cfu).
2.3 DNA extraction for control samples
DNA from an overnight culture of Klebsiella pneumoniae
NCTC 13443 was extracted using the DNeasy Blood and
Tissue Kit (Qiagen, UK) following the bacterial extraction
protocol as described by the manufacturer. The eluted DNA
was quantified on a Qubit® fluorometer using DNA assay
reagents.
2.4 Collection and characterization of urine samples
To evaluate our assay performance with urine samples of var-
iable composition, we collected urine from different healthy
volunteers. Samples were collected with ethical approval from
the Southampton Research Biorespository Access Committee
(Ref: 12/NW/0794). Approximately 50 mL of mid-stream
urine was collected into a polypropylene tube and immediate-
ly filter sterilized using a Millex syringe filter (Millipore). The
conductivity and pH of the urine samples were measured
using a Horiba B-171 conductivity meter (Horiba, UK) and
a pH indicator strip.
2.5 Cell capture experiments
Bacteria were captured using 500 nm diameter magnetic
beads coated with diethylaminoethyl (DEAE) (SiMAG-
DEAE, 500 nm @ 7.5 × 1011 particles mL−1, Chemicell,
USA) (Guo et al. 2009; Yang et al. 2011). The first step in
the protocol was to establish the number of bacteria in the
culture that adhered to the beads i.e. the efficiency of capture.
A culture with an initial cell concentration of approximately
109 cfu mL−1 was diluted 100 times with filtered urine to
107 cfu mL−1. A 5 μl aliquot of DEAE bead stock suspension
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was added to the sample and mixed by gentle inversions until
the solution appeared homogeneous. The samples were then
incubated for 5 mins at room temperature without mixing to
promote attachment of bacteria to the beads. The beads were
removed from the solution by placing the tubes on a magnetic
rack (Promega, UK). To estimate the capture efficiency, the
concentration of bacteria in the initial culture (A) and the
supernatant (B) (after removing magnetic beads) were com-
pared. The per cent capture efficiency was calculated as
100-(B/A ×100).
2.6 Sample preparation device
The operating principle of the bead capture device is shown in
Fig. 1. The sample is the target organism (Klebsiella
pneumoniae) coupled to magnetic nanoparticles (DEAE)
and is pushed through the device using a pipette. The device
consists of a long serpentine channel that provides a defined
hydraulic resistance to control the flow rate of particles
flowing through the magnetic bead capture chamber where
the beads are captured. The urine sample minus the beads is
collected in the waste chamber. A multichannel electronic
pipette was used to deliver samples into eight parallel channels
at a constant flow rate defined by the hydrodynamic resistance
of the serpentine channel. For a given cross section, the flow
rate of the sample across the magnets can be varied by chang-
ing the channel length. The capture chamber is located above
a pair of bar-shaped permanent magnets separated by a dis-
tance of 1 mm (Fig. 1a), that are mounted in a base plate. The
bead-bacteria complexes are captured in a chamber with a
volume of approximately 6.5 μL that is closed with a thin
layer of tape. After capture, the concentrated bead-bacteria
complexes can either be removed from this chamber, or heated
in-situ to lyse the bacteria and release the DNA using a resis-
tive heater placed between the magnets and the device
(Fig. 1b). The lysate containing DNA, lysed cells and mag-
netic beads in urine is retrieved for DNA amplification.
The microfluidic bead concentration device (8 channels) is
mounted in a holder that holds the magnets and the resistive
heater. The disposablemicrofluidic devices clips into the hold-
er during operation. A schematic representation of the device
assembly is shown in Fig. 2a. The device was fabricated from
sheets of poly-(methyl methacrylate) (PMMA), which were
cut using a CO2 laser (Epilog laser mini, USA). Layer 1
formed the base of the device; layer 2 contained sample inlets,
microfluidic channels, capture chambers and the waste cham-
bers; layer 3 sealed the channels while providing access to the
capture chambers; and layer 4 provided depth to the chip.
Layers 1, 2 and 3 were fabricated from thin sheets of
PMMA (175 μm PMMA, Goodfellow, UK) while layer 4
was made from 5 mm thick PMMA (Techsoft, UK). First,
the microfluidic channels (~140 μm width, 313 mm length),
beads capture chambers (hexagon shape, 4.6 × 3 mm) and
waste chambers (35 × 6 mm) were cut into 175 μm thick
PMMA. This sheet was coated on both sides with double-
sided tape (467 MP, 50 μm, 3 M) (layer 2). Layer 2
(148×82 mm) was then bonded to layer 1 (148×82 mm)
and layer 3 (148×82 mm) to seal the microfluidic channels
(Fig. 2a) whilst allowing access to the bead capture chamber.



















Fig. 1 a Schematic representation of the sample preparation device
showing a single channel. A long microfluidic serpentine channel
controls the flow rate of a sample (bead-bacteria complexes in urine)
pushed through the device with a pipette. This connects to a small
volume bead capture chamber, placed above a pair of permanent
magnets, and a 1 mL waste chamber (diagram not to scale). b Cross
sectional view of the device along the dotted line shown in Fig. 1a. The
chip is placed in a holder, which contains the magnets for bead-bacteria
complex concentration and heater for thermal lysis of the bacteria
18 Page 4 of 10 Biomed Microdevices (2016) 18: 18
micromachined PMMA substrate (5 mm) with rectangular
windows for access to the capture chambers.
The chip holder was fabricated from laser cut PMMA
(Fig. 2b). The bottom layer (204× 108 mm) of the holder
contained 9 slots (8 × 4 mm) to hold the magnets
(Neodymium, max operating temperature 100 °C, 48 M
magnetisation strength, Supermagnet, Germany). A Kapton
insulated flexible heater (1×10 cm, Omega, UK) was placed
above the magnets to heat the chips. The heater was connected
to a Proportional Integral-Derivative (PID) (EMKO, ESM-
4420, Turkey) to maintain the chip temperature at 95 °C.
The chip was fixed into the holder in such a way that each
bead capture chamber was above a pair of magnets as shown
in Fig. 1a. A pipette-to-chip adapter was made to house the
conical shape pipette tips and fabricated using a 3D printer
(Objet, Stratasys, USA). The adapter was made from a pro-
prietary rubber-like material (FX9043) that provided a perfect
fit for the pipette tips (Fig. 2c). It provided an easy, simple, and
leak-free interface between the sample preparation chip and
pipette. Prior to use, the capture chambers were closed using a
clear, removable PCR film (Eppendorf, UK).
To operate the device, the chip was placed into the holder.
A 1 mL urine sample (with beads) was pushed through the
microfluidic channels at a constant flow rate using the 8-
channel electronic pipette. The bead-bacteria complexes were
captured in the chambers and the supernatant was collected in
the waste chamber. The chip was then removed from the hold-
er, the waste chambers emptied and the PCR film covering the
capture chambers removed so that the beads (in 6.4 μL urine)
could be recovered for further processing.
2.7 Bacteria concentration on device and lysis off device
A bacterial culture of K. pneumoniae with an initial concen-
tration of approximately 108 cfu mL−1 was diluted serially




Fig. 2 Diagram of a the sample preparation device assembly and b the
holder. The chips is made of four PMMA layers machined using a CO2
laser. Layer 1 (thickness = 175 μm) forms the base of the device, layer 2
(175 μm PMMA+2× 50 μm of double sided tape on both sides) defines
the channels (width ~140 μm) and bead capture chambers, layer 3
(175 μm) contains access holes for the bead capture chamber and seals
the micro-channels. Layer 4 (5 mm) provides depth to the chip and holds
the pipette-to-chip adapter. b the holder contains the permanent magnets
placed in slots which are separated by a distance of 1 mm. Red lines in the
figure show the position of the Kapton heater strip that is placed above the
magnets. c Cross sectional diagram of the pipette-to-chip adapter that
interfaces with an 8-channel electronic micropipette. The adapter is
fabricated using a 3D printer from a rubber-like material and
accommodates the conical pipette tips. d Photograph of the device
showing the 8 channel pipette; bead-target complexes are immobilised
in the chamber while supernatant is collected in the waste chamber
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Each experiment consisted of triplicate dilution series and the
experiment was repeated 3 times using urine from different
volunteers. Figure 3 shows the workflow for the assay. Urine
samples (1 mL) containing bacteria were spiked with 5 μl
DEAE stock bead suspension and mixed by gentle inversions
until the solution appeared homogeneous. The samples were
then incubated for 5 mins at room temperature without mixing
to promote attachment of bacteria to the beads. The sample
was pushed through the device using the multichannel pipette
at approximately 300 μL min−1 and the beads were concen-
trated into a volume of 6.4 μL. After removing the PCR film,
the 6.4 μL sample was aspirated from the collection chambers
and transferred to a clean 1.5 mL microcentrifuge tube. These
tubes were placed immediately on a heat block and incubated
at 95 °C for 5 mins to lyse the bacteria and release the DNA.
The final crude lysate contained DNA, DEAE beads and lysed
cells in the 6.4 μL of urine.
2.8 Bacteria concentration and lysis on device
Cell lysis was also performed on device using the resistive
film heater. The temperature in the chamber was measured
using a K type thermocouple (RS components, UK) placed
in one of the capture chambers. The heater was set to a target
temperature of 95 °C. After heating the bead-bacteria com-
plexes for 5 min, the chambers were allowed to cool
(approximately 30 s) and the samples were recovered for
DNA amplification by RPA.
2.9 Real time recombinase polymerase amplification assay
Real time RPA was used to amplify the blaCTX-M-15 gene,
using the TwistAmp® Exo kit. according to the manufac-
turer’s protocols. Lyophilised RPA proteins were reconstituted
with a mix comprising rehydration solution, forward and re-
verse primers and sample. In each 50 μL reaction, the final
concentrations of primers and FAM labelled probe were
0.48 μM and 0.12 μM, respectively. A 5 μl aliquot of the
urine sample with the beads and lysed cells was added to this
mix. Each RPA reaction mix was transferred to a well of
a non-binding, black polystyrene 96-well plate (Corning,
UK). The amplification reaction was initiated by adding
magnesium acetate to a final concentration of 14 mM
and mixing the reaction vigorously. The plate was trans-
ferred to a GloMax microplate reader (Promega, UK)
set to 39 °C and the fluorescence measured at 1 min
intervals for 40 min. The Time to Positivity (TTP) for
each sample was measured from the time at which the
fluorescence exceeds a threshold value equal to three
times the standard deviation of the negative controls
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Fig. 3 Schematic of the assay workflow: a DEAE functionalized
magnetic beads are added to the urine. b The sample is incubated for
5 min at room temperature to promote attachment of the beads to the
bacteria. c Sample is concentrated from 1 mL to 6.4 μL using the
sample preparation device. (C1) The bacteria-bead complex can be
aspirated from the bead capture chamber, transferred to a
microcentrifuge tube and the collected sample is heated at 95 ° C on a
heat block (D2). Alternatively, (C2) the sample is heated on the device
using a resistive heater to a temperature of 95 °C to lyse the cells and
release DNA. (E) Sample containing DNA, cell lysate, DEAE beads in
urine is used for RPA reaction
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3 Results and discussion
3.1 Sample preparation device
Traditional bench-top protocols for DNA extraction from bac-
teria captured on magnetic beads require numerous pipetting
steps and can introduce inaccuracies in the final sample vol-
ume due to various factors such as adhesion of sample to the
microcentrifuge tubes and pipetting errors. Hence, the pre-
concentration device was key to streamlining the sample prep-
aration protocol, concentrating the pathogens into a defined
sample volume that is ready for cell lysis and DNA
amplification.
The bead immobilization efficiency of the device was first
measured as a function of flow rates. The electronic pipette
provides a constant displacement so that the flow rate through
the device depended on the hydrodynamic resistance of the
channel. To determine the optimum flow rate, 5 μL of beads
(7.5×1011 particles mL−1) were suspended in 1 mL of PBS
and flowed through the device at different rates by varying the
channel length to change the hydrodynamic resistance.
Figure 4 shows the percentage of beads captured in the cham-
ber for three different flow rates. The bead immobilization
efficiency varied from 93 % at a flow rate of 100 μL min−1
(sample processing time=10 min) to approximately 35 % for
a flow rate of 1200 μL min−1 (sample processing time =
< 1 min). A flow rate of approximately 300 μL min−1 was
chosen as a compromise between a reasonable processing
time and a high bead immobilization efficiency of 85 %.
Using this flow rate, all 8 samples could be processed in par-
allel in approximately 3.5 min. The orientation of the magnets
in the holder was also assessed. It was found that the best
trapping efficiency was for N-S orientation, this dropped by
12 % for N-N (or S-S) orientation.
3.2 Capture of bacteria on DEAE beads
The anion-exchange DEAE beads captured Klebsiella
pneumoniae NCTC 13443 bacteria in human urine with a
variable efficiency of between 18 and 39 % for an incubation
time of 5 min, at a cell density of 107 cfu mL−1 (Fig. 5). This
density was used to mimic a typical heavily contaminated UTI
sample. This is important to avoid the possibility of false neg-
ative tests failing to detect the presence of low numbers of
ESBL gene-carrying bacteria, for example, in a mixed infec-
tion. Samples from four healthy volunteers showed significant
variation in capture efficiency. Conductivity measurements
were used to estimate the of salt concentration of the urine,
and this ranged from 3.6 to 20 mS cm−1 with a mean of
12.5 mS cm−1 (Table S1) well within the normal range for
human urine (Fazil Marickar 2010). The pH was also within
the range that might be expected for healthy urine samples.
There was no correlation between the conductivity and the
efficiency of cell capture. The capture efficiency measured is
in keeping with the range reported with other protocols in the
literature, even when these are carried out in water or buffer
solutions. For example, the capture efficiency of E. coli using
DEAE magnetic beads was reported to be near 100 % (Yang
et al. 2011), but the cells were suspended in H2O and incubat-
ed for 20 min. Other approaches using beads functionalized
with antibodies (Zhu et al. 2011; Wen et al. 2013; Cho et al.
2014; Suh et al. 2014), aptamers (Suh et al. 2014) or vanco-
mycin (Wang et al. 2014), generally require longer incubation
times to achieve maximum capture efficiencies ranging from
2–98, 13 and 23%, respectively. Additionally, these tests were
only performed with bacteria suspended in either buffer or
Flow rate (L min-1)























Fig. 4 The percentage of beads captured in the chamber (bead
immobilization efficiency) of the sample preparation device vs sample
flow rate. Each data point is the average of immobilization efficiencies of
the 8 channels on a single device (n = 1). Error bars represent S.D
between the efficiency in the 8 channels. The flow rate was varied by
changing the hydrodynamic resistance, hence the microfluidic channel
dimension


















Fig. 5 Average capture efficiency of Klebsiella pneumoniae NCTC
13443 (± standard deviation, n = 3) spiked into filtered urine from four
healthy volunteers (V1-4), using anion - exchange DEAE magnetic
beads. The error bar for V3 is too small to be depicted on the graph
Biomed Microdevices (2016) 18: 18 Page 7 of 10 18
water. In contrast, our protocol is quick, does not require any
bead conjugation and performs well with human urine.
3.3 Amplification of the CTX-M gene in the presence
of beads and urine
The RPA reaction performed well in the presence of DEAE
beads and urine as evidenced by the steep rise in fluorescence
during exponential amplification (Fig. 6; Figure S1) and a TTP
that compared well with previous results for pure DNA (Kalsi
et al. 2015). RPA has a high tolerance to impurities, meaning
that nucleic acid isolation and purification is often not required,
even for complex sample matrices such as human serum
(Kersting et al. 2014a, b), goat pleural fluid (Liljander et al.
2015) and human urine (Krõlov et al. 2014). In this work we
demonstrate amplification of bacterial DNA directly from heat
lysed bacteria in human urine, as previously reported for
Chlamydia trachomatis (Krolov et al. 2014). The RPA also
works well in the presence of the magnetic nanoparticles, onto
which the heat lysed bacterial cells, and possibly the released
DNA, may remain attached. In conclusion, the RPA assay per-
forms well using magnetic bead cell pre-concentration and
unpurified DNA amplification from urine samples.
Samples of bacteria spiked into urine samples from three
different volunteers (Table S1) showed a minimum reliable
limit of detection (LoD) of 1000 cfu (total spiked in assay),
with a TTP of approximately 17–18mins (Fig. 6). This LoD is
likely to be an underestimate as the actual number of cells
captured by the beads is lower than initially spiked into the
urine samples. As expected, the TTP decreases with increas-
ing bacterial counts, indicating that the assay does not saturate
at high cell numbers, within the ranges tested. A complicated
urinary tract infection (UTI) is defined by a pathogen load of
>105 cfu mL−1 in women and 104 cfu mL−1 in men, and for an
uncomplicated UTI a bacterial count of 103 cfu mL−1 is con-
sidered to be clinically relevant (Grabe et al. 2013). Our assay
shows excellent performance in this range and, with a LoD of
1000 cfu from an initial 1 mL urine sample, is suitable for
clinical diagnosis of antibiotic resistant pathogens in both
complicated and uncomplicated UTIs.
Although the LoD of 1000 cfu in our assay is sufficient for
a diagnostic test, it is higher than the usual detection limits for
RPA of 10 gene copies using pure DNA (Piepenburg et al.
Bacteria density (log cfu mL-1)
























Fig. 6 Plot of average time to positivity (TTP) of RPA reactions against
the number of cells spiked into filtered human urine (n = 3). A linear
regression is plotted for each experiment showing that the TTP is
approximately proportional to the density of bacteria (Exp. 1
R2 = 0.9218; Exp. 2 R2 = 0.732; Exp. 3 R2 = 0.8715). The limit of
detection is at or below 1000 cells for Experiment 1 and 3, and 100
cells in Experiment 2
Time (minutes)

















Heat lysis off device
Heat lysis on device
Fig. 7 A comparison of average DNA amplification curves (± standard
deviation, n = 3) for identical samples pre-concentrated on the sample
preparation device and subjected to heat lysis either on the device or off
the device in amicrocentrifuge tube. The sample heated on the device shows
faster amplification and a much higher reproducibility among replicates
Bacteria density (log cfu mL-1)





















Fig. 8 Data for an example end-to-end assay with heat lysis performed
on the sample preparation device. Capture efficiency of bacteria,
evaluated at 107 cfu, was 26.6 %. The data is the average time to
positivity (TTP) of reactions against the logarithm of the number of
cells (n= 3). A linear regression shows that TTP is proportional to the
density of bacteria (R2 = 0.9636). The limit of detection is 1000 cells
spiked into filtered human urine
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2006; Kalsi et al. 2015; Xia et al. 2015) or 10 bacterial path-
ogens lysed in urine, Krolov et al. (2014)). The higher LoD is
partly due to a higher background signal when DEAE micro-
particles are present presumably as they scatter the light. Also,
if the cell lysates are attached to the beads, the DNAmight not
be as easily accessible to the RPA primers as for a pure solu-
tion. Therefore, the assay is a compromise, sacrificing some
sensitivity for simplicity and time, while maintaining a clini-
cally relevant limit of detection.
Our simple single step sample preparation device, is able to
reduce the sample volume from 1mL to approximately 5μL in
a few minutes. The device also able to directly heat the sample
to lyse cells. A comparison of RPA data for on-chip and off-
chip heat lysis (Fig. 7) showed that there is a clear improvement
in the TTP and a reduction in the S.D, probably due to reduc-
tion in losses from manual handling. The use of an integrated
heater significantly improved the assay quality. Klebsiella
pneumoniae spiked into urine at 107 bacteria cfu showed a
capture efficiency of 26.6%,which is within the range obtained
in the capture efficiency experiments shown in Fig. 5. A bac-
teria titration over a wide range of cell densities (103-106 cfu)
was obtained on the device with integrated heater. This showed
that the coefficient of variation (CV) of TTP in the RPA assay
was lower than 5 % for all samples (Fig. 8), in contrast to the
CV for samples heated off the device, where the CV ranged
from 3.5 to 60 % in all previous experiments (mean=22.5 %).
This result confirmed the much higher reproducibility obtained
when performing lysis on the device. It also confirmed the
detection of ~266 captured cells (1000 spiked cells with capture
efficiency of 26.6 %) with RPA in under 20 min. The final
protocol takes approximately 45 min from sample to result,
including 5 min incubation of the urine sample with beads,
3.5 min to concentrate the sample, 5 min for the heat lysis
and 20 min for the RPA, with additional time (~12 min) for
handling and RPA reagent preparation.
4 Conclusions
We have demonstrated a simple device for capture and pre-
concentration of bacteria spiked into human urine, followed
by heat lysis for DNA amplification using RPA. The simple
disposable device is easy to use and relies on the use of anion-
exchange beads and DNA amplification from crude heat lysed
cells, eliminating the need for centrifugation, bead
functionalization and DNA purification. Sample handing
and reproducibility is greatly improved by the use of on-chip
heating. Cells can be pre-concentrated from 1 mL of urine
within 3.5 min. Heat lysis of cells on the device followed by
RPA delivers a simple integrated sample preparation system
for processing a urine sample to amplification-ready DNA.
We anticipate that the system and protocols developed could
have widespread use in any application where bacteria need to
be pre-concentrated from a liquid sample matrix using mag-
netic beads.
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